Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02064036 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02064036 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 17 participants.
The verdict
NCT02064036, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
We hypothesize that Stereotactic Body Radiotherapy Boost (SBRT) as a boost to the prostate following whole pelvic intensity modulated radiotherapy (IMRT) can be delivered effectively and safely in a population of men with unfavorable intermediate and high risk localized prostate cancer. Our primary objective is to assess the feasibility and safety of a treatment strategy incorporating whole pelvic IMRT followed by an SBRT boost to the prostate with neoadjuvant, concurrent, and adjuvant androgen deprivation for a total of 28 months for men with unfavorable intermediate or high risk localized prostate cancer.
Interventions
- DRUG Leuprolide
- DRUG Casodex
- RADIATION Stereotactic Radiosurgical Boost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2013-06-06 |
| Est. Completion | 2021-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02064036
The ClinicalTrials.gov registry entry for NCT02064036 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Leuprolide is the first listed.
NCT02064036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02064036 about?
NCT02064036 is a clinical study titled "Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate". We hypothesize that Stereotactic Body Radiotherapy Boost (SBRT) as a boost to the prostate following whole pelvic intensity modulated radiotherapy (IMRT) can be delivered effectively and safely in a population of men with unfavorable intermediate and high risk localized prostate cancer. Our primary...
What is the current status of trial NCT02064036?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2013-06-06. Estimated completion is 2021-10-29.
What interventions are being tested in trial NCT02064036?
The interventions under investigation include: Leuprolide (DRUG), Casodex (DRUG), Stereotactic Radiosurgical Boost (RADIATION).
Who is sponsoring clinical trial NCT02064036?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.